Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Sunitinib (SU011248)
DRUG
2 trials
Sponsors
Pfizer
, Alberta Health services
Conditions
Hormone Refractory
Liver Neoplasms
Prostate Cancer
Unresectable Hepatocellular Carcinoma
Phase 2
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Completed
NCT00247676
Pfizer
Liver Neoplasms, Unresectable Hepatocellular Carcinoma
Start: 2006-02-28
End: 2009-02-28
Updated: 2010-02-18
Sutent Maintenance After Response to Taxotere
NCT00550810
Alberta Health services
Hormone Refractory, Prostate Cancer
Start: 2007-10-31
End: 2012-11-30
Target: 30
Updated: 2011-12-07
Related Papers
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
2011-07-25
18 citations
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
2009-07-06
208 citations